Single-Use Syringe Market Report

Due to the market demand for safety syringes for surgeries as well as rising consumer demand from the pharmaceutical industry, demand for disposable syringes devices has greatly expanded over the years. single-use syringes are frequently used during modern medicine to inject drugs, sample blood, and provide immunizations. They are typically used in place of reusable syringes to prevent the transmission of disease. Two common uses for single-use syringes include the injection of insulin by a diabetic and the delivery of local anaesthesia by a dentist. The rising geriatric population, a population that is more susceptible to chronic diseases like diabetes and other lifestyle-related problems, is another reason that is anticipated to contribute to the requirement for single-use syringes in a variety of healthcare settings. Adults 65 years of age and older are also more prone to develop heart disease, COPS, diabetes, cancer, neurological issues, and other chronic illnesses, according to the CDC. Such diseases need both emergency and non-emergency hospital care, which is anticipated to drive market expansion in the near future.

One of the main factors affecting the segment is the rising awareness of blood donations throughout the global. For instance, 16 million blood components are transfused each year in the United States, according to the American National Red Cross. Additionally, the prevalence of chronic diseases like Crohn's disease and diabetes, which may be treated with self-injectable medicine, is rising. For instance, International Diabetes Federation's estimates that by 2045, around 783 million adults, or 1 in 8, will have diabetes, marking a 46% rise. Considering their importance during the administration of medications and tests, syringes are necessary for the majority of diagnostic and therapeutic approaches for chronic diseases, going to drive up demand for the product.

Stringent regulatory requirements and standards for production and disposal contribute to increased compliance costs and can delay market entry for new products. Fluctuating raw material costs, including plastics and polymers, affect production expenses and profit margins. Innovations such as reusable syringes and needle-free injection systems present competitive alternatives, potentially reducing waste and long-term costs. Budget limitations in healthcare systems, particularly in developing nations, further hinder the adoption of single-use syringes due to their higher cost compared to reusable options. Additionally, disease outbreaks or health crises can disrupt supply chains, prioritizing resources for urgent needs and affecting syringe availability. Intense competition among manufacturers may lead to price wars and diminished profit margins, while the complexity of producing high-quality syringes increases operational costs and inefficiencies. Furthermore, limitations in current manufacturing technologies and materials constrain product innovation, and legal challenges related to intellectual property can impact market entry and competitive positioning.

Major industry leaders utilize strategies that focus on launching new products, merging with competitors, and purchasing companies to grow their customer base and enhance their range of products. In March 2024, BD (Becton, Dickinson and Company) addressed the FDA’s recent safety communication on plastic syringes, noting that their products are not affected by the updates. BD has proactively increased U.S. production at its Nebraska and Connecticut facilities to meet rising demand and ensure uninterrupted patient care. Highlighting their longstanding commitment to safety and quality, BD emphasized their role in manufacturing 2 billion syringes during the COVID-19 pandemic and affirmed ongoing support for healthcare providers with any inquiries related to their syringes.

Furthermore, in June 2024, Novo Nordisk announced plans to build a new 1.4 million-square-foot manufacturing facility in Clayton, North Carolina, to expand its production of injectable therapies, including Wegovy and Ozempic. This new plant will focus on filling and packaging syringes and injection pens. The expansion reflects Novo Nordisk's response to rising demand and intermittent supply shortages for these popular medications. The facility, set to be operational between 2027 and 2029, will employ 1,000 new workers, boosting the company's existing workforce in the region.

Due to the presence of significant syringe manufacturers with substantial manufacturing capacity as well as big pharmaceutical companies, the North American market accounted for the largest revenue share, which has resulted in a rise in demand for single-use syringes. The favourable government regulations that permit the use of disposable prefilled syringes for vaccine vaccinations have enhanced the demand for single-use syringes. 

In terms of revenue share, the Asia Pacific market came in second place as the market for single-use syringes is expanding in this region, especially in India, Japan, and China, as a result of the rising prevalence of infectious diseases, increased funding and collaborations between major corporations and governments for the production and export of syringes, and the presence of sizable syringe manufacturing facilities and units, particularly in India. India's government and Directorate General of Foreign Trade (DGFT) abolished prohibitions on the export of syringes in February 2022, with immediate effect. According to India Brand Equity Foundation in Union Budget 2022-23 US$ 11.28 billion was allocated to the Ministry of Health and Family Welfare (MoHFW).

In terms of revenue share, Europe ranked second. This is related to a stronger focus on pharmaceutical products that are better and generic forms of medications and pharmaceuticals that are delivered using syringes, which are also considerably boosting demand for single-use syringes and propelling revenue growth in this region's market.